CAR T cells continue to show efficacy for the treatment of relapsed and/or refractory large B cell lymphoma.
Recent data from the ZUMA-1 and JULIET trials demonstrates that chimeric antigen receptor (CAR) T cells targeting the B cell surface receptor CD19 can induce durable disease remission in 30-40% of patients with cancer that relapsed and/or ceased responding to first-line therapies.
CAR T cells are genetically engineered to express a unique and modifiable cell surface receptor that enables the direct identification and destruction of cancerous cells.
While treatment with CAR T cells has been associated with severe and potentially life-threatening side effects, these trials demonstrated no unexpected toxicities at two-year follow-up. Future studies will continue to increase the safety, efficacy, and accessibility of this therapeutic option over the next decade.
Maloney DG. (2019) Anti-CD19 CAR T cell therapy for lymphoma — off to the races! Nature Reviews Clinical Oncology. https://doi.org/10.1038/s41571-019-0183-7
“Malignant Mesothelioma, coronal CT scan.
Legend: the malignant mesothelioma is indicated by yellow arrows, the central pleural effusion is marked with a yellow star. (1) right lung, (2) spine, (3) left lung, (4) ribs, (5) aorta, (6) spleen, (7) left kidney, (8) right kidney, (9) liver.” Source: self-made, based on Image:Tumor Mesothelioma2.JPG. Author: Stevenfruitsmaak.